Becker Capital Management’s Trinity Biotech TRIB Stock Holding History

Becker Capital Management’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7K	Hold	600	–	–	﹤0.01%	303
2026 Q1	$9.76K	Hold	600	–	–	﹤0.01%	298
2025 Q4	$14.2K	Hold	600	–	–	﹤0.01%	300
2025 Q3	$18.7K	Hold	600	–	–	﹤0.01%	293
2025 Q2	$11.7K	Hold	600	–	–	﹤0.01%	278
2025 Q1	$10.3K	Hold	600	–	–	﹤0.01%	274
2024 Q4	$15.8K	Hold	600	–	–	﹤0.01%	271
2024 Q3	$19.8K	Hold	600	–	–	﹤0.01%	275
2024 Q2	$38.3K	Hold	600	–	–	﹤0.01%	265
2024 Q1	$36.7K	Hold	600	–	–	﹤0.01%	263
2023 Q4	$38.6K	Buy	+600	New	+$43K	﹤0.01%	263

Other funds holding TRIB

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $868M AUM 32.25% 1-Year Est. Return

Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

MAWA

Moss Adams Wealth Advisors Seattle, Washington $1.6B AUM 28.24% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Becker Capital Management's TRIB Position: Q2 2026 in Review

Becker Capital Management held its Trinity Biotech (TRIB) position steady in Q2 2026 at 600 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #303.

Becker Capital Management first reported a position in TRIB in Q4 2023 and has held it in 11 quarters since. The position peaked at $38.6K in Q4 2023. 19 funds tracked by Wall St. Rank hold TRIB as of Q2 2026.

Becker Capital Management held 600 shares of Trinity Biotech worth $7K as of Q2 2026.
Becker Capital Management left its Trinity Biotech share count unchanged in Q2 2026.
Trinity Biotech made up ﹤0.01% of Becker Capital Management's portfolio in Q2 2026, its #303 holding.
Becker Capital Management first reported a position in Trinity Biotech in Q4 2023 and has held it in 11 quarters since.
Becker Capital Management's Trinity Biotech position peaked at $38.6K in Q4 2023.
19 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2026.

Based on Becker Capital Management's 13F filing for Q2 2026, filed 31 Jul 2026.